Ross Kedl, PhD

Professor of Immunology & Microbiology
University of Colorado

Ross KedlDr. Kedl received his PhD in 1997 in the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. Before joining the Faculty at the University of Colorado, Dr. Kedl was at 3M Pharmaceuticals working in their small molecule immune response modifier program. In his three years there, he spearheaded efforts at developing novel vaccine adjuvants, resulting in numerous publications and patents in the area of vaccine technology. Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer.

Biography from University of Colorado.

IDIGH Calendar

<<  <  December 2019  >  >>
 Mo  Tu  We  Th  Fr  Sa  Su 
        1
  2  3  5  6  7  8
  9101112131415
161718202122
23242526272829
3031     

Latest IDIGH Publications

  1. Kennedy, J. M., Georges, A., Bassenden, A. V., Vidal, S. M., Berghuis, A. M., Taniuchi, I., Majewski, J., Lathrop, M., Behr, M. A., Langlais, D. & Gros, P.
    (2019)
    .
    ZBTB7B (ThPOK) IS REQUIRED FOR PATHOGENESIS OF CEREBRAL MALARIA AND PROTECTION AGAINST PULMONARY TUBERCULOSIS
    .
    Infection and immunity
  2. Cook, L., Lisko, D. J., Wong, M. Q., Garcia, R. V., Himmel, M. E., Seidman, E. G., Bressler, B., Levings, M. K. & Steiner, T. S.
    (2019)
    .
    Analysis of flagellin-specific adaptive immunity reveals links to dysbiosis in patients with Inflammatory Bowel Disease
    .
    Cellular and molecular gastroenterology and hepatology
  3. Hassan, A. S., Zelt, N. H., Perera, D. J., Ndao, M. & Ward, B. J.
    (2019)
    .
    Vaccination against the digestive enzyme Cathepsin B using a YS1646 Salmonella enterica Typhimurium vector provides almost complete protection against Schistosoma mansoni challenge in a mouse model
    .
    PLoS neglected tropical diseases
    ,
    vol
    .
    13
    ,
    p
    .
    e0007490
    .
  4. Pokharel, G., Deardon, R., Barnabe, C., Bykerk, V., Bartlett, S. J., Bessette, L., Boire, G., Hitchon, C. A., Keystone, E., Pope, J., Schieir, O., Tin, D., Thorne, C., Hazlewood, G. S., Canadian Early Arthritis Cohort (CATCH) Investigators., Baron, M., Bessette, L., Boire, G., Bykerk, V., Colmegna, I., Fallavollita, S., Haaland, D., Haraoui, P., Hazlewood, G., Hitchon, C., Jamal, S., Joshi, R., Keystone, E., Nair, B., Panopoulos, P., Penney, C., Pope, J., Rubin, L., Thorne, C., Villeneuve, E. & Zummer, M.
    (2019)
    .
    Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis
    .
    ACR open rheumatology
    ,
    vol
    .
    1
    ,
    p
    .
    471-479
    .
  5. Mashock, M. J., Faron, M. L., Carroll, K. C., Dang, C., Lewis, S., Salimnia, H., Lephart, P., Loo, V. G., Schmitt, B. H., Young, S., Buchan, B. W. & Ledeboer, N. A.
    (2019)
    .
    A Multi-Center Study of the Revogene® C. difficile System for Detection of the Toxin B Gene from Unformed Stool Specimens
    .
    Journal of clinical microbiology
More publications